Summary
FDA granted accelerated approval to AstraZeneca’s ULTOMIRIS on October 21, 2026, to reduce proteinuria in adults with primary IgAN at risk of progression.
It is the fifth US rare disease indication for ULTOMIRIS and the first and only C5 inhibitor approved for this use.
In I CAN, 24-hour UPCR fell 46.6% with ULTOMIRIS vs 5.6% with placebo at Week 34 (43.4% placebo-adjusted), with effects seen as early as Week 10.
The ULTOMIRIS MoA is terminal complement (C5) inhibition, distinct from Fabhalta's Factor B target.
Continued approval depends on Week 106 eGFR data; no comparative efficacy claims versus other IgA nephropathy medications can be drawn ...